CreERT2

CreERT2 Targeted Transgenic Mouse Model
  • Live
  • Mouse
  • Male & Female Available
  • Black
  • Not available for direct purchase by CRO
Model No.NomenclatureGenotype
10471-FC57BL/6-Gt(ROSA)26Sortm9(Cre/ESR1)Arteki/ki
10471-MC57BL/6-Gt(ROSA)26Sortm9(Cre/ESR1)Arteki/ki
View:
Select One

Overview

Nomenclature: C57BL/6-Gt(ROSA)26Sortm9(Cre/ESR1)Arte

  • Inducible general Cre deleter
  • Tight and inducible regulation of Cre activity after tamoxifen administration
  • Successful ubiquitous induction of Cre activity after tamoxifen administration in all tissues analyzed. Efficiency of deletion varies between different organs and different loxP flanked (floxed) target genes but usually exceeds 70%, except in the brain were deletion efficiency is lower.
  • If a strain is maintained by homozygous sibling matings, breeders should be handled carefully and quietly to avoid poor breeding, loss of litters, or premature death
  • For the generation of the experimental colony which will be used for induction of deletion of a floxed target gene, it is mandatory to always maintain the CreER in a heterozygous state, to diminish noninduced background recombination and possible side effects. In addition, background recombination may be enhanced, if embryos are exposed to CreER(T2) carrying mothers. It is therefore strongly recommended to breed CreER(T2) negative females which are heterozygous or homozygous for the floxed allele to CreER(T2) positive males which are wild type, heterozygous, or homozygous for the floxed allele. To avoid unwanted deletion of the floxed allele, it is strongly recommended to monitor the status of the floxed allele in the offspring from these breedings and to maintain the floxed parental line also in the absence of CreER(T2).
  • When proper induction conditions are used, side effects are only seen in tamoxifen induced homozygous CreERT2 mice. Side effects include illness and lethality of tamoxifen induced animals, which may occur between 5 and 15 days after induction. Symptoms include: reduced mobility, weight loss, severe sustained diarrhea, and death. To avoid side effects, homozygous CreERT2 mice should not be induced. Taconic recommends a starting dose of 4.55 mg per dose for mice weighing 23 grams and 3 mg per dose for mice weighing 23 grams. Dosing should be by oral gavage. If side effects are seen, dose reduction should be pursued with monitoring of deletion of the target gene. Taconic recommends a pilot study with the proper experimental and control cohorts to optimize the induction protocol and to monitor the deletion of the floxed allele. Such pilots can be performed by Taconic.
  • Ligand-independent Cre activity may occur at a low level and is likely due to proteolysis of the Cre fusion protein and subsequent nuclear transport. Our experience with breeding CreERT2 to a variety of floxed target genes is that approximately 25% of floxed alleles displaying some degree of ligand-independent Cre recombination. Among those floxed alleles affected, the percent of animals examined containing one or more copies of the recombined allele varied from below 1% to as high as 98%. Learn more by reading the related Taconic Insight, "Cre/loxP Recombination System: Applications, Best Practices, and Breeding Strategies".
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin

The CreERT2 mouse was developed by Artemis Pharmaceuticals (now Taconic). The model was created by a targeted mutation knock in of high affinity CreERT2 (cre/ESR1) into the Gt(ROSA)26 locus on chromosome 6 in C57BL/6NTac ES cells. Cre/ESR1 was generated by fusion of the Cre (bacteriophage P1) gene to the high affinity human estrogen receptor gene ESR1. Cre/ESR1 is expressed under the control of the Gt(ROSA)26Sor gene. Additional sequence elements are adenovirus major late transcript splice acceptor sequence from the intron 1/ exon2 boundary situated 5´ and FLP recombinase target (FRT) sequences (Saccharomyces cerevisiae) situated 3´ of CreER. The colony is maintained by incrossing homozygous mice.

Genetics

Species:Mouse
Strain Type:Inbred
Allele Type:Recombinase-expressing; Targeted transgenic
Coat Color:Black
Genetic Background:C57BL/6

Guides & Publications

Initial Publication: Seibler J, Zevnik B, Küter-Luks B, Andreas S, Kern H, Hennek T, Rode A, Hiemann C, Faust N, Kauselmann G, Schoor M, Jaenisch R, Rajewsky K, Kühn R, Schwenk F. (2003) Rapid generation of inducible mouse mutants. Nucleic Acids Res 31(4):e12.

Applications & Therapeutic Areas

  • Recombinase-mediated Gene Deletion
  • Transgenic Model Generation Support

Transit, Housing & Welfare

Need more info? Click the live chat button or Contact Us

Packing Practices

Taconic standard practice is to recombine animals of different home cages and/or ages from a single model and sex during packing, except in specific cases where Taconic's animal welfare policy prohibits recombination due to aggression or other concerns.  When an order is fulfilled with animals from more than one week of birth, this standard practice results in animals from a range of birth weeks packed together in a single TTC. When an order is fulfilled with animals from genotyped models, this standard practice results in animals from different home cages packed together in a single TTC.

Customers who wish to keep animals from different weeks of birth separated should place orders with the special instruction "Divide and label by age."  Note that this special request can result in increased costs for additional Taconic Transit Cages, dividers and/or freight charges.

Licensing

Access to the Taconic CreERT2 model 10471 requires execution of a CreERT2 Research Crossbreeding Agreement. The fees for a CreERT2 Research Crossbreeding Agreement that permits crossing of the Taconic CreERT2 model 10471 to ONE (1) floxed line is:
  • $5,780/€5,260 per year for nonprofit users
  • $27,525/€25,080 per year for for-profit users

 


A 20% reduction of the CreERT2 Research Crossbreeding Agreement fees is offered if breeding is done at Taconic.

Pricing - USD

Opportunist Free (OF) Health Standard

10471 Female

10471-F Genotype ki/ki

Age in WeeksQuantity 1 - 999
3 to 10$449.00

10471 Male

10471-M Genotype ki/ki

Age in WeeksQuantity 1 - 999
3 to 10$449.00

Pricing - EUR

Opportunist Free (OF) Health Standard

10471 Female

10471-F Genotype ki/ki

Age in WeeksQuantity 1 - 999
3 to 10€404,00

10471 Male

10471-M Genotype ki/ki

Age in WeeksQuantity 1 - 999
3 to 10€404,00

Select my Health Standard

Need help choosing the right Taconic Biosciences health standard for your research?

Use the Health Standard Selector to enter your exclusion list. The tool will tell you which health standards meet your requirements.

Get custom pricing guide

2024 Pricing Guide Now Available

Get your Taconic Biosciences 2024 Pricing Guide today. Personalized, customizable, links to up-to-date health reports, and additional information on Taconic's products and services.

Looking for More Information

Schedule A Scientific Consultation

We provide you with coupled capabilities and service offerings, enabling your researchers to work with a single provider to meet their study needs while enjoying a more streamlined integrated process at any stage of a project.

Speak with a Colony Management Specialist and Field Application Scientist that can help you develop and deploy the tailored solution you need.

Want to Get in Touch?

Chat with us or reach out to our global team

phone

2024 Pricing Guide Now Available

Get your Taconic Biosciences 2024 Pricing Guide today. Personalized, customizable, links to up-to-date health reports, and additional information on Taconic's products and services.